IFN-γ-Induced IDO in Connective Tissue Cell Populations
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for autoimmune diseases and inflammatory disorders are inadequate, often leading to severe side effects and limited efficacy, with a need for new therapies that can modulate the immune system effectively without compromising the patient's defense against infections.
Innovation Solution
Isolation of a cell population from connective tissue that does not express IDO constitutively but induces IDO upon interferon-gamma (IFN-γ) stimulation, capable of differentiating into multiple lineages and acting as immunoregulatory agents to treat autoimmune diseases and inflammatory disorders.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If immunosuppressive agents are administered to treat autoimmune diseases, then the autoimmune disease is treated more effectively, but the patient becomes more susceptible to infections and tumors
Solution Approach 1:
The patent applies local quality by inducing IDO expression specifically in connective tissue-derived cells through IFN-γ stimulation, creating localized immunosuppressive activity at the site of autoimmune pathology rather than systemic immunosuppression. This targeted approach suppresses autoimmune responses in affected tissues while preserving systemic immune defense against infections and tumors
Solution Approach 2:
The patent utilizes parameter changes by modulating the immunoregulatory function of connective tissue-derived cells through controlled IDO induction. By changing the expression level of IDO in response to IFN-γ stimulation, the cells achieve immunosuppressive effects that are可调 (adjustable) and responsive to inflammatory signals, rather than constitutive suppression
2Ease of operation
If current therapies are used to treat inflammatory disorders, then some symptom relief is achieved, but the treatment provides less than adequate results with severe side effects
Solution Approach 1:
The patent employs self-service by utilizing the endogenous IFN-γ cytokine produced during inflammatory responses to induce IDO expression in connective tissue-derived cells. The cells automatically respond to the inflammatory environment by upregulating IDO, creating a self-regulating immunosuppressive mechanism that adapts to the disease state without requiring external immunosuppressive drugs
Solution Approach 2:
The patent introduces connective tissue-derived cells expressing IDO as an intermediary between the inflammatory response and immunosuppression. These cells act as mediators that translate IFN-γ signals into immunoregulatory effects, providing a bridge between pro-inflammatory and anti-inflammatory pathways
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The described cell population effectively ameliorates symptoms of autoimmune diseases and inflammatory disorders by inducing immunotolerance, reducing inflammation, and promoting regulatory T-cell responses, offering a safer and more targeted therapeutic approach.
Implementation Method 1
respond to interferon-gamma (IFN-γ) by expressing indolamine-2,3-dioxygenase (IDO)
Implementation Method 2
expressing indolamine-2,3-dioxygenase (IDO)
Data Source
Figure 1
Figure 2A
Figure 2B
AI summary
The present invention provides a population of connective tissue derived cells that respond to interferon-gamma (IFN-γ) by expressing indolamine-2,3-dioxygenase (IDO) for use in preventing, treating or ameliorating one or more symptoms associated with disorders in which modulation of a subject's immune system is beneficial, including, but not limited to, autoimmune diseases, inflammatory disorders, and immunologically mediated diseases including rejection of transplanted organs and tissues.